Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma

Acta Oncologica

Volumn 48, Issue 1, 2009, Pages 154-156

  Soetekouw, Patricia M M B ^a   Koopman, M ^b   Burger, David ^b   Tjan Heijnen, Vivianne C G ^a   De Mulder, P H M ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALPHA2B INTERFERON; BEVACIZUMAB; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; INSULIN; PLACEBO;

ADULT; ADVANCED CANCER; ANAMNESIS; CANCER PALLIATIVE THERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; KIDNEY CARCINOMA; KIDNEY FAILURE; LABORATORY TEST; LETTER; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

CARCINOMA, RENAL CELL; HUMANS; HYPERGLYCEMIA; HYPONATREMIA; INTERFERON ALFA-2B; KIDNEY NEOPLASMS; MALE; MIDDLE AGED;

EID: 58149093788     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802047403     Document Type: Letter

References (20)

1. Jemal A, Thomax A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Escudier B. Advanced renal cell carcinoma: Current and emerging management strategies. Drugs 2007;67:1257-64.
3. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
4. Chen LK, Hwang SJ, Tsai ST, Luo JC, Lee SD, Chang FY. Glucose intolerance in Chinese patients with chronic hepatitis C. World J Gastroenterol 2003;9:505-8.
5. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998;28:514-7.
6. Chedin P, Cahen-Varsaux J, Boyer N. Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1996;125:521.
7. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989;38:641-7.
8. Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987;2(8573):1423-7.
9. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MachLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993;260(5116):1942-6.
10. Pankewycz OG, Guan JX, Benedict JF. Cytokines as mediators of autoimmune diabetes and diabetic complications. Endocr Rev 1995;16:164-76. (Review)
11. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26(3 Suppl 1):112S-121S.
12. Shiba T, Higashi N, Nishimura Y. Hyperglycaemia due to insulin resistance caused by interferon-gamma. Diabet Med 1998;15:435-6.
13. Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, de Gast GC. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother 2005;54:713-9.
14. Lopes EP, Oliveira PM, Silva AE, Ferraz ML, Costa CH, Miranda W, Dib SA. Exacerbation of type 2 diabetes mellitus during interferon-alpha therapy for chronic hepatitis B. Lancet 1994;343(8891):244.
15. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
16. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
17. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-58.
18. Sasso FC, Carbonara O, Di Micco P, Coppola L, Torella R, Niglio A. A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy. Br J Clin Pharmacol 2003;56:238-9.
19. Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006;18:689-92.
20. Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, de Lalla F. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000;23:1177-81.